Last reviewed · How we verify
NCT06822413
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
trial testing No Interventions in Cancer Diagnosis in 600 participants. Currently enrolling.
15 May 2025
Quick facts
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 1 September 2022 |
| Primary completion | 15 May 2025 |
| Estimated completion | 28 July 2025 |
| Sites | 4 locations across China |
Drugs / interventions tested
- No Interventions — full drug profile →
Conditions studied
- Cancer Diagnosis — all drugs for Cancer Diagnosis →
- Liver Cancer, Adult — all drugs for Liver Cancer, Adult →
- Cancer Screening — all drugs for Cancer Screening →
- Colorectal Cancer (CRC) — all drugs for Colorectal Cancer (CRC) →
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Who can join
Eligibility, any sex, with Cancer Diagnosis or Liver Cancer, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are: * Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk. * Identifying which model is more adaptable to the Raman spectrum * Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies.
Anees M, Sherry C, Park HY, Grayhack EE, et al · · 2026 · PMID 41866828 · DOI 10.1002/ctm2.70594
Verify or expand the search:
- PubMed search for NCT06822413
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No Interventions
Trials testing the same drug.
- NCT07473284 — Incidence and Characteristic of CRT Persistent After Catheter Extraction in ICU Patients · not yet recruiting
- NCT07413380 — Effects of Arm Measurements on Upper Limb Skills and Reaction Time · NA · not yet recruiting
- NCT07536711 — Ego-Tucking: Exploring the Psychological Mechanisms of the "Fo-xi" Phenomenon Among University Students · completed
- NCT07409376 — Comparison of the Therapeutic Effects of Balloon Assisted Enteroscopy Assisted Narrow Incision and Balloon Dilation in t · NA · not yet recruiting
- NCT07356115 — Association of High PainDETECT Scores With Pain Region and Diagnosis in Patients Attending a Musculoskeletal and Sports · recruiting
Other recruiting trials for Cancer Diagnosis
Currently open trials in the same condition.
- NCT07416513 — Digital Solutions for bEtter cAre · NA · recruiting
- NCT06523868 — Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study · NA · recruiting
- NCT06645691 — Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body · Phase 2 · recruiting
- NCT06502483 — PRISM for Depression and Anxiety in Young Adults With Cancer · NA · active not recruiting
- NCT05142033 — Avera Cancer Sequencing and Analytics Protocol (ASAP) · recruiting
Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials
Trials by the same sponsor.
- NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
- NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
- NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
- NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
- NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06822413 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06822413.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing